Results 101 to 110 of about 67,526 (234)
Ivermectin Toxicity in Humans and Animals: Clinical Spectrum, Mechanisms, and Management
Journal of Applied Toxicology, EarlyView.ABSTRACT Ivermectin is a widely used macrocyclic lactone with established efficacy against a broad range of parasitic infections in humans and animals and a long‐standing reputation for clinical safety. However, increasing evidence indicates that ivermectin can produce clinically relevant toxicity under specific conditions, particularly involving the ...
Serkan Yilmaz +3 more
wiley +1 more source
How Can We Move Clinical Genomics Beyond the Hype? [PDF]
, 2011 Examines the debate over increased use of genetic testing, due in part to lax regulation, and its consequences: wasteful spending, patient harm, and health system challenges.
Michael L. Millenson
core
Journal of Clinical Laboratory Analysis, EarlyView.This study developed a PCR‐based fragment analysis assay for UGT1A1 rs3064744 targeting TA5 (*36), TA6 (*1), TA7 (*28), and TA8 (*37). The assay was CLIA validated with data showing 100% concordance and a sensitivity of 0.5 ng/uL. The assay was then implemented in a patient cohort of n = 940 and the results compared with PharmacoScan.
Ryan N. Baugher +6 more
wiley +1 more source
Clinical applications of personalized medicine: a new paradigm and challenge [PDF]
, 2017 The personalized medicine is an emergent and rapidly developing method of clinical practice that uses new technologies to provide decisions in regard to the prediction, prevention, diagnosis and treatment of disease.
Borro, Marina +7 more
core +1 more source
Lipids, EarlyView.ABSTRACT Ischemic stroke is frequently associated with symptomatic intracranial atherosclerotic stenosis (sICAS), is a leading cause of global disability and mortality. Current guidelines recommend dual antiplatelet and intensive statin therapies. Proprotein convertase subtilisin 9/kexin type 9 (PCSK9) inhibitors have emerged as a potent lipid‐lowering
Chao Zhao +5 more
wiley +1 more source
Movement Disorders Associated with 22q11.2 Microdeletion: A Scoping Review
Movement Disorders Clinical Practice, EarlyView.Abstract Background Movement disorders have recently emerged as important neurologic manifestations of the 22q11.2 microdeletion that affects nearly one in every 2000 live births. Objective We aimed to map the existing evidence regarding the spectrum, diagnosis and treatment, and etiopathogenesis of movement disorders associated with 22q11.2 ...
Nikolai Gil D. Reyes +6 more
wiley +1 more source
PLoS Computational Biology, 2012 There is great variation in drug-response phenotypes, and a "one size fits all" paradigm for drug delivery is flawed. Pharmacogenomics is the study of how human genetic information impacts drug response, and it aims to improve efficacy and reduced side ...
Konrad J Karczewski +3 more
doaj +1 more source
Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adults. [PDF]
, 2019 Adverse drug reactions (ADRs) contribute to hospitalization but data on its economic burden is scant. Pre-emptive pharmacogenetic (PGx) testing can potentially reduce ADRs and its associated costs.
Brunham, Liam R +6 more
core +1 more source
The genomics of neonatal abstinence syndrome [PDF]
, 2017 Significant variability has been observed in the development and severity of neonatal abstinence syndrome (NAS) among neonates exposed to prenatal opioids.
Cole, F. Sessions +2 more
core +3 more sources
Pediatric Anesthesia, EarlyView.ABSTRACT Background Emergence delirium (ED) is a common complication in pediatric anesthesia. Although intranasal dexmedetomidine (DEX) is widely used, its application is constrained by a slow onset, residual risk of ED in some patients, and risks such as bradycardia and hypotension.
Munder Lateiresh +5 more
wiley +1 more source